Lipid nanoparticles (LNP) targeting PD-L1 effectively target glioma tissues, inhibit PD-L1 or eliminate TAMCs, which are immunosuppressive cells, strengthen anti-tumor immunity, and extend the survival time of mice. This evidence concerns the gene CD274 and central nervous system cancer.